Boticarium

  1. Medrano Albéniz, Juan
Revista:
Revista de la Asociación Española de Neuropsiquiatría

ISSN: 0211-5735

Año de publicación: 2014

Volumen: 34

Número: 123

Páginas: 599-609

Tipo: Artículo

DIALNET GOOGLE SCHOLAR lock_openAcceso abierto editor

Otras publicaciones en: Revista de la Asociación Española de Neuropsiquiatría

Resumen

Esta sección se nutre de fuentes de libre acceso en Internet, lo que condiciona su contenido. Por una parte, no incluye artículos recientes de revistas "de impacto", generalmente restringidos a suscriptores. Por otra parte, recoge aportaciones publicadas en números relativamente antiguos que, transcurrido el tiempo que imponen las publicaciones correspondientes, pasan a ser de consulta gratuita en la red. Por último, alguna de las fuentes no cumple el estricto requisito de ser revisada por pares, pero se trata de publicaciones de cierto prestigio que divulgan revisiones de valor, o de informaciones periodísticas o recensiones de interés informativo porque desarrollan y resumen artículos que no pueden leerse en su integridad por el momento en Internet. Para consultar alguna de las fuentes el lector interesado deberá registrarse, un trámite que se realiza en muy poco tiempo, no compromete a nada y permite el acceso autónomo a la revista en el futuro.

Referencias bibliográficas

  • (1) Quetiapine and QTc prolongation. Medicines Safety Update 2014; 5 (1), February 2014. Accesible en: http://www.tga. gov.au/hp/msu-2014-01.htm#prolongation
  • (2) U.S. Food and Drug Administration. Seroquel (quetiapine fumarate). Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER). October 2013. Accesible en: http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm374025.htm
  • (3) U.S. Food and Drug Administration. Seroquel XR (quetiapine fumarate) Extended-Release tablets. Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER), October 2013. Accesible en: http://www.fda. gov/Safety/MedWatch/SafetyInformation/ ucm196974.htm
  • (4) Srivastava A, Patil V, Da Silva Pereira Y. A Case Series of Quetiapine Addiction/Dependence. German J Psychiatry 2013; 16: 152-5. Accesible en: http://www.gjpsy. uni-goettingen.de/gjp-article-srivastava2.pdf
  • (5) Smith TL, Mican LM, Ellingrod VL. What to do when your patient who takes clozapine enters a smoke-free facility. Current Psychiatry 2014; 13(5): 47-48, 57. Accesible en: http://www.currentpsychiatry.com/ articles/savvy-psychopharmacology/article/ what-to-do-when-your-patient-who-takesclozapine-enters-a-smoke-free-facility/7dd0741a68c948ee9a9db4fb473934ee.html
  • (6) Tully J, Sim C, Hemani R, Munir M, Khalil N, Fahy S. Audit of monitoring of the parameters of metabolic syndrome in patients on clozapine. The Psychiatrist Online 2012; 36: 466-9. Accesible en: http://pb.rcpsych.org/content/36/12/466.full.pdf+html
  • (7) Fazel S, Zetterqvist J, Larsson H, Långström N, Lichtenstein P. Antipsychotics, mood stabilisers, and risk of violent crime. Lancet 2014. pii: S0140-6736(14)60379-2.doi: 10.1016/S0140-6736(14)60379-2. Accesible en: http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(14)60379- 2/fulltext
  • (8) Kaspar R, Ellingrod VL. Strategies for managing drug-induced tardive dyskinesia. Cuurent Psychiatry 2014; 13(3): 44-46. Accesible en: http://www.currentpsy- chiatry.com/articles/savvy-psychopharmacology/article/strategies-for-managing-drug-induced-tardive-dyskinesia/6d10e2d8e395155363a0e22eb7b37c2e.html
  • (9) Mizuno Y, Suzuki T, Nakagawa A, Yoshida K, Mimura M, Fleischhacker WW, Uchida H. Pharmacological Strategies to Counteract Antipsychotic-Induced Weight Gain and Metabolic Adverse Effects in Schizophrenia: A Systematic Review and Meta-analysis. Schizophr Bull. 2014 Mar 17. [Epub ahead of print]. Accesible en: http:// schizophreniabulletin.oxfordjournals.org/ content/early/2014/03/15/schbul.sbu030.abstract
  • (10) Duloxetine and serotonin síndrome. Medicines Safety Update 2013; 4(6), December 2013. Accesible en: http://www. tga.gov.au/hp/msu-2013-06.htm#duloxetine
  • (11) Agencia Española de Medicamentos y Productos Sanitarios. Citalopram y prolongación del intervalo QT del electrocardiograma. Fecha de publicación: 27 de octubre de 2011. Accesible en: http://www. aemps.gob.es/informa/notasInformativas/medicamentosUsoHumano/seguridad/2011/NIMUH_19-2011.htm.
  • (12) Agencia Española de Medicamentos y Productos Sanitarios. Escitalopram: Prolongación del intervalo QT del electrocardiograma. 2 de diciembre de 2011. Accesible en: http://www.aemps.gob.es/informa/notasInformativas/medicamentosUsoHumano/ seguridad/2011/docs/NI-MUH_23-2011.pdf
  • (13) Zivin K, Pfeiffer PN, Bohnert AS, Ganoczy D, Blow FC, Nallamothu BK, et al. Evaluation of the FDA warning against prescribing citalopram at doses exceeding 40 mg. Am J Psychiatry 2013; 170: 642- 50. doi: 10.1176/appi.ajp.2013.12030408. Abstract en: http://www.ncbi.nlm.nih.gov/ pubmed/23640689
  • (14) Bird ST, Crentsil V, Temple R, Pinheiro S, Demczar D, Stone M. Cardiac safety concerns remain for citalopram at dosages above 40 mg/day. Am J Psychiatry 2014; 171:17-9.
  • (15) Watts V. FDA Responds to AJP Manuscript on Citalopram Safety. January 31, 2014 DOI: 10.1176/appi. pn.2014.1b2. Accesible en: http://psychnews. psychiatryonline.org/newsarticle.aspx?articleid=1827911
  • (16) Drye LT, Spragg D, Devanand DP, Frangakis C, Marano C, Meinert CL, et al. Changes in QTc Interval in the Citalopram for Agitation in Alzheimer’s Disease (CitAD) Randomized Trial. PLoS One 2014; 9(6): e98426. doi: 10.1371/journal.pone.0098426. Accesible en: http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal. pone.0098426
  • (17) Porsteinsson AP, Drye LT, Pollock BG, Devanand DP, Frangakis C, Ismail Z, et al. Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial. JAMA 2014; 311: 682-91. Abstract en: http://jama.jamanetwork.com/article. aspx?articleid=1829989.
  • (18) Miller M, Swanson SA, Azrael D, Pate V, Stürmer T. Antidepressant Dose, Age, and the Risk of Deliberate Self-harm. JAMA Intern Med 2014; 174: 899-909. Abstract en: http://www.ncbi.nlm.nih.gov/ pubmed/24782035.
  • (19) Miller M, Pate V, Swanson SA, Azrael D, White A, Stürmer T. Antidepressant class, age, and the risk of deliberate self-harm: a propensity score matched cohort study of SSRI and SNRI users in the USA. CNS Drugs 2014; 28: 79-88. Abstract en: http:// www.ncbi.nlm.nih.gov/pubmed/24146116.
  • (20) López A. Un nuevo fármaco para los sofocos. El Mundo, 1 de julio de 2013. Accesible en: http://www.elmundo.es/elmundosalud/2013/07/01/mujer/1372702192.html
  • (21) Orleans RJ, Li L, Kim MJ, Guo J, Sobhan M, Soule L, Joffe HV. FDA approval of paroxetine for menopausal hot flushes. N Engl J Med 2014; 370: 1777-9.
  • (22) Agencia Española del Medicamento y Productos Sanitarios. Restablecimiento del suministro de Tofranil 10 mg, 60 comprimidos y Tofranil 25 mg, 50 comprimidos. 14 de abril de 2014. Accesible en: http://www.aemps.gob.es/informa/notasInformativas/medicamentosUsoHumano/problemasSuministro/2014/NI_ICM-CONT_05- 2014-tofranil.htm
  • (23) Vicente Sánchez MP, Macías Saint-Gerons D, de la Fuente Honrubia C, González Bermejo D, Montero Corominas D, Catalá-López F. Evolución del uso de medicamentos ansiolíticos e hipnóticos en España durante el período 2000-2011. Rev Esp Salud Publica 2013; 87: 247-55. Accesible en: http:// www.scielosp.org/pdf/resp/v87n3/04_original3.pdf
  • (24) Health Canada. Health Canada Endorsed Important Safety Information on Sublinox (zolpidem tartrate). 3 enero 2014. Accesible en: http://healthycanadians.gc.ca/ recall-alert-rappel-avis/hc-sc/2014/37415aeng.php
  • (25) Agencia Española de Medicamentos y Productos Sanitarios. Zolpidem (Dal- paran®, Stilnox®, Zolpidem EFG®): Riesgo de somnolencia al día siguiente (Recomendaciones del Comité para la Evaluación de Riesgos en Farmacovigilancia europeo-PRAC), 11 de marzo de 2014. Accesible en: http://www. aemps.gob.es/informa/notasInformativas/medicamentosUsoHumano/seguridad/2014/docs/ NI-MUH_FV_05-2014-zolpidem.pdf
  • (26) Raza M, Kennedy CA, Latif S. Zolpidem may cause visual distortions and other psychotic symptoms. Current Psychiatry 2014; 13(3):31-32. Accesible en: http:// www.currentpsychiatry.com/articles/pearls/ article/zolpidem-may-cause-visual-distortions-and-other-psychotic-symptoms/6b30f7def90d221070804a5ab58dd315.html
  • (27) Ekström MP, Bornefalk-Her- mansson A, Abernethy AP, Currow DC. Safety of benzodiazepines and opioids in very severe respiratory disease: national prospective study. BMJ 2014; 348:g445. doi: 10.1136/ bmj.g445. Accesible en: http://www.bmj. com/content/348/bmj.g445.pdf%2Bhtml
  • (28) Weich S, Pearce HL, Croft P, Singh S, Crome I, Bashford J, et al. Effect of anxiolytic and hypnotic drug prescriptions on mortality hazards: retrospective cohort study. BMJ. 2014 Mar 19;348:g1996. doi: 10.1136/bmj.g1996. Accesible en: http://www.bmj.com/content/348/bmj. g1996?view=long&pmid=24647164
  • (29) U.S. Food and Drug Administration. FDA Drug Safety Communication: FDA warns of serious skin reactions with the anti-seizure drug Onfi (clobazam) and has approved label changes, 12/3/2013. Accesible en: http://www.fda.gov/Drugs/DrugSafety/ ucm377204.htm?source=govdelivery&utm_ medium=email&utm_source=govdelivery
  • (30) Serrani Azcurra DJ. Retratamiento con lamotrigina después de reacción cutánea de rash. Estudio de casos abiertos y metaanálisis combinados. Rev Psiquiatr Salud Ment 2013; 6:144-9. Accesible en: http:// zl.elsevier.es/es/revista/revista-psiquiatriasalud-mental-286/articulo/retratamiento-conlamotrigina-despues-reaccion-90250062
  • (31) U.S. Drug and Food Administration. Tegretol (carbamazepine) Tablets, Chewable Tablets, Oral Suspension, and Tegretol-XR (carbamazepine extended-release) Tablets. Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER). January 2014. Accesible en: http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm346734.htm
  • (32) U.S. Food and Drug Administration. Stavzor (valproic acid) Delayed Release Capsules. Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER). March 2014. Accesible en: http://www.fda. gov/Safety/MedWatch/SafetyInformation/ ucm360495.htm
  • (33) U.S. Food and Drug Administration. Topamax (topiramate) tablets and sprinkle capsules. Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER). October 2012. Accesible en: http://www.fda. gov/Safety/MedWatch/SafetyInformation/ ucm195797.htm
  • (34) Dinesh KMK, Rajmohan V, Viji KG, Joshi M. Topiramate-Induced Bilateral Angle-Closure Glaucoma. German J Psychiatry 2013; 16: 122-123. Accesible en: http:// www.gjpsy.uni-goettingen.de/gjp-article-kumar-topiramate.pdf
  • (35) Carter L, Zolezzi M, Lewczyk A. An updated review of the optimal lithium dosage regimen for renal protection. Can J Psychiatry 2013; 58: 595-600. Accesible en: http://publications.cpa-apc.org/media. php?mid=1568
  • (36) Robinson S, Meeks TW, Geniza C. Medications for alcohol use disorder. Which agents work best? Current Psychiatry 2014; 13(1): 22-30, 32. Accesible en: http://www.currentpsychiatry.com/uploads/ media/022_0114CP_Robinson_Cov_FINAL. pdf
  • (37) U.S. Food and Drug Administration. Revia (naltrexone HCl) tablets. Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER), October 2013. Accesible en: http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm374896.htm
  • (38) Mocking RJ, Patrick Pflanz C, Pringle A, Parsons E, McTavish SF, Cowen PJ, et al. Effects of short-term varenicline administration on emotional and cognitive processing in healthy, non-smoking adults: a randomized, double-blind, study. Neuropsychopharmacology 2013; 38: 476-84. Accesible en: http://www.nature.com/npp/journal/v38/n3/pdf/npp2012205a.pdf
  • (39) Gill KE, Pierre PJ, Daunais J, Bennett AJ, Martelle S, Gage HD, et al. Chronic treatment with extended release methylphenidate does not alter dopamine systems or increase vulnerability for cocaine self-administration: a study in nonhuman primates. Neuropsychopharmacology 2012; 37: 2555-65. Accesible en: http:// www.nature.com/npp/journal/v37/n12/pdf/ npp2012117a.pdf
  • (40) Soto PL, Wilcox KM, Zhou Y, Kumar A, Ator NA, Riddle MA, et al. Longterm exposure to oral methylphenidate or dl-amphetamine mixture in peri-adolescent rhesus monkeys: effects on physiology, behavior, and dopamine system development. Neuropsychopharmacology 2012; 37: 2566- 79. Accesible en: http://www.nature.com/npp/ journal/v37/n12/pdf/npp2012119a.pdf
  • (41) Volkow ND. Long-term safety of stimulant use for ADHD: findings from nonhuman primates. Neuropsychopharmacology 2012; 37: 2551-2. Accesible en: http:// www.nature.com/npp/journal/v37/n12/pdf/ npp2012127a.pdf
  • (42) U.S. Food and Drug Administration. Methylphenidate ADHD Medications: Drug Safety Communication Risk of Long-lasting Erections, 12/17/2013. Ac- cesible en: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm378876.htm
  • (43) U.S: Food and Drug Administration. Strattera (atomoxetine hydrochloride) capsule Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER), February 2014. Accesible en: http://www.fda.gov/Safety/MedWatch/ SafetyInformation/ucm223889.htm
  • (44) Sanofi. Comunicación dirigida a los profesionales sanitarios. Metoclopramida (Primperan®, Metoclopramida EFG): Actualización de indicaciones y posología para minimizar el riesgo de efectos adversos (principalmente neurológicos). Febrero de 2014. Accesible en: https://sinaem.agemed.es/CartasFarmacovigilanciaDoc/2014/DHPCMetoclopramida-feb-07.pdf
  • (45) Healy D. The creation of psychopharmacology. Cambridge, Massachussets: Harvard University Press, 2002
  • (46) Sulpirida Kern EFG. Ficha técnica. Accesible en: http://www.aemps.gob.es/ cima/pdfs/es/ft/73195/FT_73195.pdf
  • (47) Dogmatil Fuerte 200 mg. Ficha técnica. Accesible en: http://www.aemps.gob. es/cima/pdfs/es/ft/73195/FT_73195.pdf
  • (48) Trichard C, Paillére-Martinot M-L, Attar-Levy D, Recassens C, Monnet F, Martinot J-L. Binding of Antipsychotic Drugs to Cortical 5-HT2A Receptors: A PET Study of Chlorpromazine, Clozapine, and Amisulpride in Schizophrenic Patients. Am J Psychiatry 1998; 155:505-8. Abstract en: http:// www.ncbi.nlm.nih.gov/pubmed/9545996
  • (49) Bressan RA, Erlandsson K, Jones HM, et al. Is Regionally Selective D2/D3 Dopamine Occupancy Sufficient for Atypical Antipsychotic Effect? An In Vivo Quantitative [123I]Epidepride SPET Study of Amisulpride-Treated Patients. Am J Psychiatry 2003; 160:1413-1420. Abstract en: http://www.ncbi. nlm.nih.gov/pubmed/12900302
  • (50) Leucht S, Pitschel-Walz G, Engel RR, Kissling W. Amisulpride, an Unusual “Atypical” Antipsychotic: A Meta-Analysis of Randomized Controlled Trials. Am J Psychiatry 2002; 159:180-90. Abstract en: http:// www.ncbi.nlm.nih.gov/pubmed/11823257
  • (51) Bailly-Salin P. Allergies au largactil dans les années 55: une histoire oubliée. Inf Psychiatr 1998; 74: 493-499. Abstract en: http://psydoc-fr.broca.inserm.fr/bibliothq/revues/InfoPsy/Infopsy598.html
Fuente de los datos: Dialnet